Published in Cancer Gene Ther on January 01, 2006
Fluorescence-guided surgery allows for more complete resection of pancreatic cancer, resulting in longer disease-free survival compared with standard surgery in orthotopic mouse models. J Am Coll Surg (2012) 2.24
Hand-held high-resolution fluorescence imaging system for fluorescence-guided surgery of patient and cell-line pancreatic tumors growing orthotopically in nude mice. J Surg Res (2013) 1.47
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med (2014) 1.44
Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer. Ann Surg Oncol (2014) 1.25
Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res (2012) 1.25
A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther (2008) 1.09
Fluorescence-guided surgery and fluorescence laparoscopy for gastrointestinal cancers in clinically-relevant mouse models. Gastroenterol Res Pract (2013) 1.04
Fluorescence-assisted cytological testing (FACT): Ex Vivo viral method for enhancing detection of rare cancer cells in body fluids. Mol Med (2011) 0.94
Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? Viruses (2015) 0.92
Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden. Curr Protoc Pharmacol (2011) 0.91
Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery. FASEB J (2006) 0.90
Application of GFP imaging in cancer. Lab Invest (2015) 0.90
Imaging of lymph node micrometastases using an oncolytic herpes virus and [F]FEAU PET. PLoS One (2009) 0.87
Animal models and molecular imaging tools to investigate lymph node metastases. J Mol Med (Berl) (2011) 0.87
Fluorescence-guided surgery improves outcome in an orthotopic osteosarcoma nude-mouse model. J Orthop Res (2014) 0.82
Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs (2008) 0.81
Regional liver therapy using oncolytic virus to target hepatic colorectal metastases. Semin Oncol (2010) 0.80
Virally-directed fluorescent imaging (VFI) can facilitate endoscopic staging. Surg Endosc (2006) 0.78
Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses. Front Oncol (2017) 0.75
FACS-optimized mutants of the green fluorescent protein (GFP). Gene (1996) 24.12
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther (2000) 4.33
Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med (1995) 3.37
Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A (2000) 3.24
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther (2000) 2.94
Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res (2001) 2.50
The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci U S A (1996) 2.09
Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med (1977) 2.01
Lung cancer--time to move on from chemotherapy. N Engl J Med (2002) 2.00
Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res (1997) 2.00
The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer (1985) 1.97
Visualizing gene expression by whole-body fluorescence imaging. Proc Natl Acad Sci U S A (2000) 1.72
Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J (1999) 1.64
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther (2002) 1.51
Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia (1999) 1.44
Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther (2002) 1.39
In vivo tumor delivery of the green fluorescent protein gene to report future occurrence of metastasis. Cancer Gene Ther (2000) 1.37
Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther (2002) 1.26
Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J (2004) 1.24
Visualization of the metastatic process by green fluorescent protein expression. Anticancer Res (1997) 1.18
The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery (2003) 1.17
Imaging liver metastases: current limitations and future prospects. Br J Radiol (2000) 1.17
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res (2001) 1.12
Metastatic patterns of lung cancer visualized live and in process by green fluorescence protein expression. Clin Exp Metastasis (1997) 1.10
Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med (2001) 1.08
Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer. Hum Gene Ther (2004) 1.08
Laparoscopic fluorescence diagnosis for intraabdominal fluorescence targeting of peritoneal carcinosis experimental studies. Ann Surg (2002) 1.07
Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther (1998) 1.07
Prognostic significance of pleural lavage cytology immediately after thoracotomy in patients with lung cancer. J Thorac Cardiovasc Surg (1993) 1.04
Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann Intern Med (1988) 1.03
Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest (2002) 1.03
Intraoperative pleural lavage cytology in lung cancer patients. Ann Thorac Surg (1991) 1.02
DNA tumor viruses -- the spies who lyse us. Curr Opin Genet Dev (2005) 1.00
Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther (1999) 1.00
Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg (2002) 0.99
Pleural cytologies in lung cancer without pleural effusions. Ann Thorac Surg (1997) 0.97
The prognostic significance of tumor cell detection in intraoperative pleural lavage and lung tissue cultures for patients with lung cancer. J Thorac Cardiovasc Surg (1997) 0.94
Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Hum Gene Ther (2001) 0.92
Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg (2002) 0.91
Improving diagnostic staging laparoscopy using intraperitoneal lavage of delta-aminolevulinic acid (ALA) for laparoscopic fluorescence diagnosis. Surgery (1999) 0.90
Pleural lavage cytology immediately after thoracotomy and before closure of the thoracic cavity for lung cancer without pleural effusion and dissemination: clinicopathologic and prognostic analysis. Ann Surg Oncol (1997) 0.89
A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: the incidence of carcinomatous pleuritis after surgical intervention. J Thorac Cardiovasc Surg (2002) 0.89
GFP-expressing mammalian cells for fast, sensitive, noninvasive cell growth assessment in a kinetic mode. Biotechnol Bioeng (1999) 0.86
The positive pleural effusion. A retrospective study of cytopathologic diagnoses with autopsy confirmation. Acta Cytol (1992) 0.85
Role of pleural lavage cytology before resection for primary lung carcinoma. Ann Surg (1999) 0.85
Thoracoscopic fluorescence diagnosis (TFD) of pleural malignancies: experimental studies. Thorax (2002) 0.84
Spectrometry supports fluorescence staging laparoscopy after intraperitoneal aminolaevulinic acid lavage for gastrointestinal tumours. J Photochem Photobiol B (2000) 0.83
Radioisotopic imaging allows optimization of adenovirus lung deposition for cystic fibrosis gene therapy. Hum Gene Ther (2001) 0.83
Noninvasive fluorescent imaging reliably estimates biomass in vivo. Biotechniques (2002) 0.81
Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein. Gene Ther (1998) 0.79
Flow cytometric assessment of transduction efficiency and cytotoxicity of herpes simplex virus type 1-based amplicon vectors. Cytometry (2001) 0.78
Prognostic value of positive pleural lavage in patients with lung cancer resection. Ann Thorac Surg (1999) 0.78
Transduction of fibroblasts and CD34+ progenitors using a selectable retroviral vector containing cDNAs encoding arylsulfatase A and CD24. J Hum Genet (2000) 0.77
Functional genomics and radioisotope-based imaging procedures. Ann Med (2003) 0.76
Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med (1999) 7.04
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg (2001) 5.94
An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology (1993) 5.41
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol (2001) 4.89
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med (2000) 4.40
Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet (1987) 4.18
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med (1988) 4.02
Structure and function of the interferon-beta enhanceosome. Cold Spring Harb Symp Quant Biol (1998) 3.81
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med (1996) 3.63
Evaluation of a polymerase chain reaction for the diagnosis of tuberculosis. Tubercle (1991) 3.58
Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg (1995) 3.31
Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet (1988) 3.30
Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci U S A (1999) 3.19
Changes in conserved region 2 of Escherichia coli sigma 70 affecting promoter recognition. J Mol Biol (1990) 3.04
Segment-oriented hepatic resection in the management of malignant neoplasms of the liver. J Am Coll Surg (1998) 3.04
Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A (2001) 3.04
Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. J Am Coll Surg (1998) 2.97
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol (1995) 2.89
Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg (1998) 2.81
Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J Biol Chem (2000) 2.62
Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg (2000) 2.60
Mitochondrial DNA molecules and virtual number of mitochondria per cell in mammalian cells. J Cell Physiol (1988) 2.59
Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg (2001) 2.57
Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg (1999) 2.57
Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol (2000) 2.48
Physician-performed point-of-care echocardiography using a laptop platform compared with physical examination in the cardiovascular patient. J Am Coll Cardiol (2001) 2.47
Worldwide esophageal cancer collaboration. Dis Esophagus (2009) 2.41
Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg (1996) 2.39
Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol (1998) 2.36
Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest (1998) 2.35
Pleurodesis using talc slurry. Chest (1994) 2.29
Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med (1991) 2.27
Nonspecific bronchial reactivity in occupational asthma. J Allergy Clin Immunol (1979) 2.22
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol (2008) 2.12
Features of myocardial injury in severe organophosphate poisoning. Clin Toxicol (Phila) (2014) 2.09
PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins. Genes Dev (1999) 2.09
Prognostic factors and recurrence pattern in node-negative advanced gastric cancer. Eur J Surg Oncol (2012) 2.05
One hundred consecutive hepatic resections. Blood loss, transfusion, and operative technique. Arch Surg (1994) 2.03
Management of 155 patients with benign liver tumours. Br J Surg (2001) 1.97
Primary sarcomas of the mediastinum: results of therapy. J Thorac Cardiovasc Surg (1998) 1.96
Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med (1980) 1.95
Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. Ann Thorac Surg (1996) 1.91
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer (2011) 1.90
Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg (2000) 1.85
Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and filamentous hemagglutinin. Infect Immun (1992) 1.85
Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J (1989) 1.82
An immunodeficiency characterized by defective signal transduction in T lymphocytes. N Engl J Med (1989) 1.79
Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol (1999) 1.75
Results of hepatic resection for sarcoma metastatic to liver. Ann Surg (2001) 1.75
Production of cytotoxic factor in the spleen of dengue virus-infected mice. Immunology (1980) 1.73
Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol (1993) 1.73
Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J (2007) 1.72
Extended hepatic resection: a 6-year retrospective study of risk factors for perioperative mortality. J Am Coll Surg (2001) 1.69
Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg (1998) 1.69
Long-term preservation and storage of mycobacteria. Appl Microbiol (1972) 1.69
Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery (1997) 1.68
Primary bony and cartilaginous sarcomas of chest wall: results of therapy. Ann Thorac Surg (1992) 1.68
Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. Diabetologia (2008) 1.67
Emergent excitations in a geometrically frustrated magnet. Nature (2002) 1.66
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol (2012) 1.65
Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J (1999) 1.64
Stenting from the vertebral artery to the posterior inferior cerebellar artery. AJNR Am J Neuroradiol (2011) 1.64
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol (2003) 1.63
Methods for the quantification of DNA double-strand breaks determined from the distribution of DNA fragment sizes measured by pulsed-field gel electrophoresis. Radiat Res (1995) 1.61
Requirement for a kinase-specific chaperone pathway in the production of a Cdk9/cyclin T1 heterodimer responsible for P-TEFb-mediated tat stimulation of HIV-1 transcription. J Biol Chem (2000) 1.59
Household income and health care expenditures in Mexico. Health Policy (1997) 1.58
Reaction of systemic lupus erythematosus antinative DNA antibodies with native DNA fragments from 20 to 1,200 base pairs. J Clin Invest (1980) 1.57
A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer (2001) 1.57
A prospective analysis of staging laparoscopy in patients with primary and secondary hepatobiliary malignancies. J Gastrointest Surg (2000) 1.57
Preservation of mycobacteria: 100 percent viability of suspensions stored at -70 C. Appl Microbiol (1973) 1.54
SGK integrates insulin and mineralocorticoid regulation of epithelial sodium transport. Am J Physiol Renal Physiol (2001) 1.54
Efficient recruitment of TFIIB and CBP-RNA polymerase II holoenzyme by an interferon-beta enhanceosome in vitro. Proc Natl Acad Sci U S A (1998) 1.54
Angiotensin-converting enzyme gene polymorphism and vascular manifestations in Korean patients with SLE. Lupus (2002) 1.53
Patients with advanced cancer: a survey of the understanding of their illness and expectations from palliative radiotherapy for symptomatic metastases. Clin Oncol (R Coll Radiol) (2001) 1.53
Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes. Blood (1982) 1.52
Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet (1990) 1.50
Cross-cultural adaptation and validation of Korean Western Ontario and McMaster Universities (WOMAC) and Lequesne osteoarthritis indices for clinical research. Osteoarthritis Cartilage (2001) 1.49
Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg (2001) 1.49
Growth factor signal transduction immediately after two-thirds partial hepatectomy in the rat. Cancer Res (1999) 1.48
Current indications and results of VATS in the evaluation and management of hemodynamically stable thoracic injuries. Eur J Cardiothorac Surg (2004) 1.48
Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy. Dis Esophagus (2013) 1.46
Coexistence of ankylosing spondylitis and mixed connective tissue disease in a single patient. Clin Exp Rheumatol (1999) 1.46
Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: a report from the Childrens Cancer Group. J Clin Oncol (1994) 1.45
Lung resection for colorectal metastases. 10-year results. Arch Surg (1992) 1.44
Postoperative fluorescence bronchoscopic surveillance in non-small cell lung cancer patients. Ann Thorac Surg (2001) 1.43
Death from metastatic donor-derived ovarian cancer in a male kidney transplant recipient. Am J Transplant (2009) 1.41
T-category reflects the histopathologic characteristics of gallbladder cancer. Eur J Surg Oncol (2012) 1.41
Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg (1995) 1.40
Quality of marital life in Korean patients with spondyloarthropathy. Clin Rheumatol (2003) 1.40
Infective crystalline keratopathy secondary to non-tuberculous mycobacterium (Mycobacterium abscessus) in a non-traumatized eye. Eye (Lond) (2007) 1.40
Use of the Hickman-Crawford critical care catheter in marrow transplant recipients: a pulmonary artery catheter-adaptable central venous access. Crit Care Med (1994) 1.39
Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. Am J Med (1988) 1.39
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol (2009) 1.39
Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene (2011) 1.39
Improvement in transfusion safety using a specially designed transfusion wristband. Transfus Med (2000) 1.38
Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Ann Oncol (2007) 1.38
Automated HPLC screening of newborns for sickle cell anemia and other hemoglobinopathies. Clin Chem (1996) 1.37